 |
|
|
| |
Second-generation HIV-1 Maturation Inhibitor BMS-955176: Overall Antiviral Activity and Safety Results from the Phase IIa Proof-of-Concept Study (AI468002)
|
| |
| |
Reported by Jules Levin
EACS 2015 Oct 20-24 Barcelona, Spain - 15th European AIDS Conference
Carey Hwang,1 Dirk Schürmann,2 Christian Sobotha,2 Marta Boffito,3
Heather Sevinsky,1 Neelanjana Ray,1 Palanikumar Ravindran,1 Hong Xiao,1
Mark Krystal,4 Ira Dicker,4 Dennis Grasela,1 and Max Lataillade,4
on behalf of the BMS HIV Global Development Team
1Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA
2Charité Research Organisation GmbH, Charitéplatz 1, 10117 Berlin, Germany
3St. Stephen's Centre, Chelsea and Westminster Hospital, London, UK
4Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA
|
| |
|
|
|
|
|
